The GRIDD Study leverages the Patient-Reported Impact of Dermatological Diseases measure.

The International Alliance of Dermatology Patient Organizations (GlobalSkin), in partnership with Cardiff University (UK), and University Medical Centre Hamburg-Eppendorf (Germany), launched the Global Research on the Impact of Dermatological Diseases (GRIDD) Study, a patient-led research partnership that aims to generate comprehensive global data on the impact of conditions of the skin, hair, nail, and mucosa on people’s lives.

The GRIDD Study leverages the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure. PRIDD was designed over a four-year period with input from nearly 2,500 patients with skin diseases from around the world to capture and quantify lived experience. This comes at a time when key agencies in public health, such as the US Food and Drug Administration and European Medicines Agency, have placed a high priority on the generation and use of Patient Experience Data (PED or PXD).

The GRIDD study is open until September 28, 2023. Eligible individuals may participate by visiting https://globalskin.org/GRIDDStudy.

A total of 10,000 adults living with skin diseases are anticipated to take part in the GRIDD Study. The survey takes 10-20 minutes to complete and is accessible in the following 17 languages: Arabic, Bengali, Chinese (simplified), English, French, Dutch, Danish, German, Hindi, Italian, Japanese, Portuguese, Russian, Serbian, Spanish, Swahili, and Vietnamese.

GRIDD data will support local, national, and international advocacy work calling for greater research investment as well as more accessible care and treatment, to ultimately improve the lives of dermatology patients. 

"This is a landmark moment for us at GlobalSkin, and indeed for the entire dermatology community,” says Jennifer Austin, GlobalSkin Chief Executive Officer, in a news release. “The launch of the GRIDD Study, following seven years of extensive research and the tireless support of our patient organization community, marks a significant step forward in our mission to enhance understanding of skin conditions and patients’ unmet needs.” 

Marc Yale, GlobalSkin Board President adds, "The GRIDD Study is an opportunity for people with skin conditions to share their unfiltered views of the day-to-day challenges they face. These individuals are disease experience experts and vital contributors in helping us gather data validating the need for improved care, better treatment options, and more affordable medicines.”

The GRIDD Study is a shining example of how people living with the condition can be at the centre of important research initiatives and make their voices heard,” says Christine Bundy PhD, AFBPS, CPsychol, Professor of Behavioural Medicine, Cardiff University - Co-lead Researcher GRIDD project.

With this unique project, we expect robust scientific data to achieve a powerful collective voice for greater and equitable access to care for people with skin diseases worldwide,” shares Prof. Dr. Matthias Augustin, MD, PhD, Professor of Dermatology and Chair of Health Economics, University Medical Center of Hamburg - Co-lead Researcher GRIDD project.